Search Results 621-630 of 18341 for alopecia

1. A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer - Mayo Clinic

   Subjects must not have unresolved clinically significant adverse events Grade ≥ 2 from prior anticancer therapy, except for alopecia or anemia. Subjects ...

2. An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy - Mayo Clinic

   For Part A only: Participants who did not recover from all clinically significant toxicities (excluding alopecia and hematologic toxicities) of any previous ...

3. https://www.mayoclinic.org/spanish_organization_concepts.xml

4. A Study of Nivolumab and Multi-fraction Stereotactic Radiosurgery with or without Ipilimumab in Treating Participants with Recurrent Grade II-III Meningioma - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); however, alopecia, sensory ...

5. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction - Mayo Clinic

   ... alopecia, unless approved by the principal investigator; biologics or immunotherapy will not be allowed within 28 days prior to, or during, romidepsin ...

6. Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy - Mayo Clinic

   Toxicities related to all prior anticancer therapies must have resolved or stabilized, apart from alopecia and peripheral neuropathy. Note: Peripheral ...

7. Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer - Mayo Clinic

   Patients who have not recovered from adverse events attributed to prior anti-cancer therapy (i.e. have residual toxicities > grade 1, except for alopecia, ...

8. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

9. Phase III Study Of Datopotamab Deruxtecan Versus Docetaxel In Previously Treated TROP2-positive Advanced Non-squamous NSCLC Without AGA - Mayo Clinic

   Participation eligibility · Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. · Has ...

10. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer - Mayo Clinic

    * Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.